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 The HIV prevention cascade: more smoke than thunder?
“All happy families are alike; each unhappy family is unhappy 
in its own way.” 
Leo Tolstoy, Anna Karenina 
The need for a call to action for HIV prevention is clear. 
The UNAIDS global estimates of the burden of HIV 
released on May 31, 2016, show continuing extraordinary 
progress in rolling out antiretroviral therapy to people 
living with HIV. Around 17 million of the 36·7 million 
people living with HIV are now accessing treatment 
leading to substantial reductions in mortality.1 By 
contrast, despite the steady rise in the proportion of 
people living with HIV on treatment, the number of new 
infections among adults has remained stubbornly high, 
with a modest 4% fall in east and southern Africa over 
the past 5 years, and an alarming increase of over 50% in 
eastern Europe and central Asia. So the HIV Prevention 
2020 Framework, laid out in this issue2 by the Global 
Prevention Focal Point Group is welcome.
The 90-90-90 target set by UNAIDS in 20143 and 
subsequently incorporated into the planning of many 
countries has been a major advocacy success in pushing 
governments and programmes to respond to the clear 
evidence that all people should be oﬀ ered treatment.4–6 
The target consists of three sequentially linked goals 
that, if achieved, would lead to 73% of individuals living 
with HIV being eﬀ ectively treated so that their virus was 
supressed. This is good for people living with HIV and 
also renders them no longer infectious. Such a simple, 
clear strategy to ﬁ nd as many people living with HIV 
as possible, to treat as many of them as possible, and 
to ensure that the treatment is as eﬀ ective as possible 
lends itself well to monitoring through an approach 
known as cascade analysis.
Two of the papers in this issue7,8 are based around the 
concept of the HIV Prevention cascade and another9 uses 
prevention cascades for each of several interventions. 
The cascade presented is from demand to supply to 
adherence, which is a useful framework for analysing 
bottlenecks and programmatic ways to improve 
outcomes. The cascade approach makes perfect sense 
when considering a set of (public health) actions that 
are consequent one upon another. This approach was 
probably ﬁ rst popularised in the Piot model proposed 
by Maurice Piot at WHO in the 1960s to describe the 
likely eﬀ ect of tuberculosis control programmes and the 
importance of each of the transitions from symptoms 
through health-seeking behaviour to accurate diagnosis 
and eﬀ ective treatment.10 Similar models have been used 
for sexually transmitted infections (the Piot-Fransen 
model, no relation to Maurice)11 and malaria.12 However, 
HIV prevention, with the exception of preventing 
mothers living with HIV from passing infection to their 
infant, does not lend itself to the same linear processes 
making the cascade concept harder to deﬁ ne, to explain, 
and to measure. Every one of the 37 million people living 
with HIV needs essentially the same thing (diagnosis, 
linkage to care, the oﬀ er of treatment and support to 
maintain viral suppression). Both the denominator and 
the numerator for each step in the cascade are intuitive 
and (at least in principle) measureable. However the 
prevention needs of the approximately 4 billion sexually 
active adults who are currently uninfected are highly 
varied and dependent on local context and individual 
behaviour. Recent advances in HIV prevention have 
aimed to expand the range of eﬀ ective approaches 
and to promote individuals’ autonomy and choice. 
The notion of combination prevention,13 emphasises 
the same multisectoral view described by Hargreaves 
and colleagues8 linking prevention to structural, 
behavioural, and biomedical interventions. Although 
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the HIV prevention cascade is described as being “similar 
to the HIV treatment cascade”, we are also advised to 
avoid confusion because “our use of the term cascade 
is diﬀ erent to the HIV treatment cascade” and not to 
“oversimplify HIV prevention”.8 Within a single key 
population, there is, of course, enormous heterogeneity, 
and by implication, there are diﬀ erent prevention needs.14 
Even the value of a condom to prevent HIV is entirely 
conditional on the likelihood of a sexual partner being 
infected and the likelihood that an infected partner is 
taking treatment and taking it eﬀ ectively. One of the 
strengths of Smith and colleagues’ model in this issue is 
that the diﬀ erent HIV prevention modalities interact.15 
The cascade begins to feel less like a cascade and more 
like a web. Garnett and colleagues,9 begin with individual 
cascades for each of several core HIV prevention 
interventions and then suggest merging sequential 
cascades. They too acknowledge the challenges of 
denominators that are hard to deﬁ ne and measure and 
may change as people come in and out of “seasons of 
risk”.16 They talk of “a population at risk of acquiring 
infection over a given period of time”, but even within 
easily identiﬁ able populations, the actual risk may vary 
enormously and “risk perception” a key element in the 
demand step of the cascade may or may not be close to 
this actual risk. For example, the recorded incidence in 
the subset of men having sex with men who returned 
for more than one HIV test at a Barcelona clinic averaged 
2·5 per 100 person-years, but a few questions about 
partnerships, sexually transmitted infections, and sexual 
behaviour disaggregated the population into groups with 
incidence of less than 1 per 100 person-years up to 25 per 
100 person years.17 Men who seek out services or trials 
that oﬀ er pre-exposure prophylaxis have substantially 
higher risk than other men from the same community, 
but they are hard to count for a cascade denominator.18
HIV prevention interventions are situated within a 
broader context, and structural interventions, such 
as keeping girls in school for more years, can lead 
to important reductions in HIV risk.19 However, the 
beneﬁ ts of longer education or improved gender 
relationships go far beyond HIV control. These 
externalities are hard to capture in a framework 
based on linear transitions towards a single objective. 
Likewise the beneﬁ ts of apparently narrowly focused 
HIV prevention interventions may extend to broader 
sexual and reproductive health beneﬁ ts and to linking 
previously undiagnosed individuals into HIV treatment 
programmes.
Cascade analysis is one of the many tools that now 
populate the ever growing ﬁ eld of a range of overlapping 
disciplines such as implementation science or operations 
research or health systems research. Its power is in 
highlighting the gaps in implementation along a 
particular well characterised pathway. Value chain 
analysis, originally conceived for maximising proﬁ ts 
within businesses may allow for a wider perspective.20 
As Garnett and colleagues9 point out, “each intervention 
can be separated out”. In the new era of the sustainable 
development goals, the emphasis is on integration and 
universal coverage. Attempting to measure the drop out 
along the process of each component of a prevention 
approach may be a strong way to improve performance 
but may not be the best overarching framework for 
prevention. The management framework and the core 
results for HIV Prevention by 20202 make prevention 
cascades just one element of quality improvement.  
When David Livingstone stumbled upon the largest 
cascade in Africa, he learned that it was called Mosi-oa-
tunya, the smoke that thunders. It would be a shame if 
the power of cascade analysis was hidden by attempts 
to shoehorn prevention frameworks into a linear model.
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